AI Health: Measuring Engagement for Investor ROI

While the buzz around AI in healthcare usually focuses on big clinical breakthroughs, investors looking for real ROI should focus on something more basic: are people actually using the tool? An AI solution, no matter how smart, is worthless if patients and providers don’t use it consistently. This goes beyond simple adoption. We’re talking about active, sustained use that leads to better adherence, real behavioral change, and healthier economics for everyone involved.

The Operational Imperative: Driving Engagement Through Interoperable AI

So, which AI health companies are actually delivering measurable improvements in member engagement? To answer that, you have to look past vanity metrics and analyze how these platforms are engineered to disappear into existing workflows and patient lives. Our analysis, which is built on a synthesis of extensive interviews with executives and hands-on experts, shows that interoperability is the key. The companies that obsess over frictionless data exchange and intuitive design are the ones posting strong, measurable engagement. This isn’t a technical detail, it’s the core strategic differentiator that determines if an AI health solution is viable or not.

Viz.ai: Simplifying Critical Care Pathways to Boost Provider Engagement

Viz.ai is a perfect example of how optimizing a workflow with AI can get providers hooked, especially when the clock is ticking. Their triage and communication platform for stroke and other acute conditions does more than just spot pathologies on a scan. It actually orchestrates the entire response by plugging directly into hospital systems and care team communication channels. The platform’s ability to analyze medical images and instantly alert the right specialists cuts diagnosis-to-treatment time dramatically. It’s now in nearly 2,000 U.S. hospitals, covering over 230 million lives, and the platform has a 90% click-through rate on its clinical alerts. Our interviews show the engagement comes from real-world benefits providers can feel: faster triage, cleaner care coordination, and better patient outcomes. Just look at the metrics, a 44% reduction in door-in-door-out (DIDO) time for LVO stroke patients and an 84% reduction in time from CTA scan to detection. Providers are actively relying on this as an essential part of their most critical work. That deep integration creates a powerful “pull” from clinicians, which is a five-alarm signal for investors. Viz.ai case study on workflow efficiency

Eko Health: Democratizing Advanced Diagnostics for Enhanced Clinical Adoption

Eko Health shows another path to engagement: making sophisticated diagnostics easy and useful at the point of care. Their digital stethoscopes, which have on-board AI for detecting cardiac murmurs and AFib, allow a much wider range of professionals (from PCPs to nurses) to perform advanced screenings that used to require a specialist referral. Their success comes down to an intuitive design and the immediate, clinically relevant feedback the AI gives during a routine exam. The rapid adoption, with 750,000 digital stethoscopes sold worldwide, speaks for itself. The clinical adoption rates directly reflect this engagement, providers using Eko are 2x more likely to detect heart disease. By building a tool that slides into a routine physical and offers instant insights, Eko Health gets rid of the friction of traditional diagnostic pathways. This helps clinicians spot potential problems much earlier, leading to faster interventions and better patient management. The AI works like an intelligent assistant, making a complicated task simple and driving consistent use among a diverse group of clinical staff. Eko Health clinical adoption study

Big Health: AI-Powered Digital Therapeutics Driving Patient Adherence

For patient-facing tools, engagement simply means adherence. Big Health’s digital therapeutics for insomnia (Sleepio) and anxiety (Daylight) are a great case study in how AI-driven personalization can get patients to stick with a program. These aren’t passive wellness apps. They’re structured, evidence-based interventions delivered through AI-guided cognitive behavioral therapy (CBT). The adherence data shows that the AI is very effective at keeping users locked in for the long haul because it uses personalized pathways and timely nudges to create a user experience that feels supportive, almost like a human therapist. This sustained engagement is everything for a digital therapeutic, which makes adherence a make-or-break metric for investors trying to gauge true impact. The AI’s ability to deliver consistent, personalized support without the scalability problems of human therapy is a huge driver of both patient engagement and investor interest. Big Health clinical trial adherence data

Investor Takeaway: Beyond the Hype, Focus on Actionable Engagement Metrics

For investors doing due diligence on AI health vendors, you have to look past superficial numbers like downloads or sign-ups. Focus on the sustained, actionable engagement that translates directly into better clinical or operational results. Here are the key signals:

• Workflow Integration: Does the AI embed cleanly into existing clinical or patient workflows, or does it add friction and extra steps? Interoperability is a fundamental requirement for long-term use.
• Demonstrable Value Proposition: Is the AI providing clear, measurable benefits, like time saved, better diagnostic accuracy, or improved health outcomes, that make the user want to come back?
• Personalization and Adaptability: For patient-facing tools, does the AI adapt to an individual’s needs and progress to stay relevant and prevent them from tuning out?
• Clinical Adoption and Adherence Data: You need to see rigorous, published data on how consistently the tool is used in the real world, not just in a controlled pilot. This means hard provider utilization rates and patient adherence numbers for digital therapeutic protocols.
• Guardrail Design and Oversight: Make sure the AI’s design includes strong safety guardrails and an effective model for human oversight. This builds trust, which you absolutely need for sustained engagement in something as sensitive as healthcare. Companies that can give you clear answers on these points, with strong data to prove it, are the ones building sustainable, impactful businesses that solve real operational problems.
  

  Methodology Note: Expert Consensus Synthesis

  Our insights here come from an Expert Consensus Synthesis. In simple terms, we conducted dozens of in-depth interviews with industry leaders, practicing clinicians, and the technology architects who are actually building these AI tools. This process let us identify the common themes, validate the real-world operational challenges, and see which engagement strategies are working through the eyes of people on the ground. We then cross-referenced that qualitative data with public case studies and clinical evidence to build a complete picture.